Jubilant Pharmova (BOM:530019) GF Value Rank: 6 (As of Sep. 21, 2026) — 14% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:530019 Jubilant Pharmova Ltd BOM:530019
68 GF Score
Price ₹1,067.15
GF Value ₹1,094.39
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Jubilant Pharmova GF Value Rank?

Jubilant Pharmova BOM:530019 +5.44% 68 GF Value Rank is 6 as of Sep. 21, 2026, which is 14% below its 10-year median of 7.00. GuruFocus rates BOM:530019 with a GF Score™ of 68/100 and a GF Value™ of ₹1,094.39 (Fairly Valued). The stock has 7 warning signs investors should review.

Jubilant Pharmova has the GF Value Rank of 6.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Jubilant Pharmova GF Value Rank Related Terms


BOM:530019 vs ZTS: GF Value Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Jubilant Pharmova's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jubilant Pharmova GF Value Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jubilant Pharmova's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Jubilant Pharmova's GF Value Rank falls into.


BOM:530019
68GF Score
Jubilant Pharmova Ltd BOM:530019
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 6 mean?
Jubilant Pharmova (BOM:530019) has a GF Value Rank of 6 as of Sep. 21, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Jubilant Pharmova and its competitors. This is 14% below median its historical median of 7.00. Over the past decade, Jubilant Pharmova's GF Value Rank has ranged from 1.00 to 10.00.
Is Jubilant Pharmova's GF Value Rank too high?
Jubilant Pharmova's current GF Value Rank of 6 is 14% below median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Jubilant Pharmova has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jubilant Pharmova's GF Value Rank compare to ZTS?
Jubilant Pharmova's GF Value Rank of 6 can be compared against companies in the Drug Manufacturers industry. Historically, Jubilant Pharmova's own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Drug Manufacturers company?
A good GF Value Rank depends on the Drug Manufacturers industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Jubilant Pharmova and its competitors. Jubilant Pharmova's current GF Value Rank is 6, which is 14% below median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jubilant Pharmova stock overvalued right now?
Based on GuruFocus' analysis, Jubilant Pharmova (BOM:530019) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,094.39, compared to a current price of ₹1,067.15 — trading 2.5% below its estimated fair value. The current GF Value Rank is 6, which is 14% below median its 10-year median of 7.00. Jubilant Pharmova's overall GF Score™ is 68/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Jubilant Pharmova (BOM:530019), the current GF Value Rank is 6 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jubilant Pharmova (BOM:530019) Overvalued in 2026?

Based on GuruFocus' analysis, Jubilant Pharmova stock appears to be undervalued. The current stock price of ₹1,067.15 is trading 2.5% below its estimated GF Value™ of ₹1,094.39. GuruFocus considers Jubilant Pharmova to be Fairly Valued.

Key valuation signals for BOM:530019:

  • GF Value Rank: 6 (14% below median its 10-year median of 7.00)
  • GF Value™: ₹1,094.39 vs. price of ₹1,067.15 (2.5% below fair value)
  • GF Score™: 68/100 with 7 warning signs

No single metric tells the full story. See the BOM:530019 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jubilant Pharmova Business Description

Other Exchanges JUBLPHARMA:India
Address 1A, Sector 16A, Noida, UP, IND, 201301
Jubilant Pharmova Ltd is an integrated pharmaceutical company. The company operates in the following segments; Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment which specializes in developing, manufacturing, commercializing, and distributing therapeutic agents in the nuclear medicine domain. Geographically, it derives a majority of its revenue from the Americas and Europe and the rest from India and the Rest of the world.
68GF Score

Get the complete analysis for BOM:530019

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,067.15
Price
₹1,094.39
GF Value